STOCK TITAN

Chemomab Therapeutics Ltd - CMMB STOCK NEWS

Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotech advancing novel therapies for fibro-inflammatory diseases. This news hub provides investors and researchers with essential updates on nebokitug (CM-101), the company's lead monoclonal antibody targeting CCL24 in conditions like primary sclerosing cholangitis (PSC) and systemic sclerosis.

Access timely reports on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes verified updates from Phase 2/3 trials, FDA/EMA designations, and scientific conference presentations. Key focus areas span biomarker validation, trial enrollment status, and intellectual property developments.

This resource serves as your central source for tracking Chemomab's progress in addressing high-need rare diseases. Bookmark this page for direct access to primary documents including SEC filings, peer-reviewed data publications, and official press releases. Check regularly for updates on the upcoming Phase 3 PSC trial and expansion into new fibrotic disease indications.

Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) reported strong progress in advancing the CM-101 Phase 2 PSC trial towards completion of enrollment, on track for topline readout in the second half of 2024. The company reiterated that cash reserves are sufficient to fund operations through the end of 2024, with decreasing quarterly cash burn expected to continue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) received a notice from the Nasdaq Listing Qualifications Department stating that the company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of its American Depositary Shares (ADSs) on the Nasdaq Capital Market. The company has until May 6, 2024, to regain compliance by having the closing bid price of its ADSs meet or exceed $1.00 per ADS for at least 10 consecutive business days. The company's ADSs will continue to trade on the Nasdaq Capital Market under the symbol 'CMMB'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.29%
Tags
none
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. will release its third quarter 2023 financial results and a business update on November 9, 2023 at 8:00 am Eastern Time. Investors can contact the company at IR@chemomab.com for further discussion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.15%
Tags
conferences earnings
Rhea-AI Summary
Chemomab Therapeutics to present at major U.S. scientific conferences in November
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Chemomab Therapeutics announces positive developments for CM-101 in the treatment of primary sclerosing cholangitis (PSC). Phase 2 SPRING trial progressing with topline data expected in H2 2024. CM-101 demonstrates dual anti-fibrotic and anti-inflammatory activity. Positive results from Phase 2a trial in NASH patients. Promising potential as a disease-modifying therapy for PSC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.35%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.22%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
management
Chemomab Therapeutics Ltd

Nasdaq:CMMB

CMMB Rankings

CMMB Stock Data

21.12M
14.12M
15.91%
25.92%
2.07%
Biotechnology
Pharmaceutical Preparations
Link
Israel
TEL AVIV